Truscreen waves away Mexican risk
After playing up its distribution partner in Latin America, the medical device minnow plays down its partner's rival patent.
Aspiring medical device maker Truscreen [NZX: TRU] says it is not concerned about its Mexican distributor developing a rival cancer screening product, despite the company claiming a US patent and announcing its plans to do so.
Chairman Robert Hunter told the company’s annual meeting in Auckland
Want to read more? It's easy.
Choose your best value subscription option
Individual
Group membership
NBR Marketplace
Yearly Premium Online Subscription
NZ$499.00 / yearly
Monthly Premium Online Subscription
NZ$44.95 / monthly
Smartphone Only Subscription
NZ$24.95 / monthly
Premium Group Membership 10 Users
NZ$350+GST / monthly
$35 per user - Pay by monthly credit card debitPremium Group Membership 20 Users
NZ$600+GST / monthly
$30 per user - Pay by monthly credit card debitPremium Group Membership 50 Users
NZ$1250+GST / monthly
$25 per user - Pay by monthly credit card debitPremium Group Membership 100 Users
NZ$1875+GST / monthly
$18.75 per user - Pay by monthly credit card debitYearly Premium Online Subscription + NBR Marketplace
NZ$499.00 / yearly
Already have an account? Login
Tim Hunter
Fri, 16 Sep 2016
Fri, 16 Sep 2016
© All content copyright NBR. Do not reproduce in any form without permission, even if you have a paid subscription.
Truscreen waves away Mexican risk
61671